GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Total Operating Expense

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Total Operating Expense : $271.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Total Operating Expense?

Taro Pharmaceutical Industries's Total Operating Expense for the three months ended in Dec. 2023 was $64.0 Mil. Taro Pharmaceutical Industries's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $271.3 Mil.


Taro Pharmaceutical Industries Total Operating Expense Historical Data

The historical data trend for Taro Pharmaceutical Industries's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Total Operating Expense Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.21 153.19 151.51 168.22 250.61

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.77 66.43 72.01 68.86 64.00

Taro Pharmaceutical Industries Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $271.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taro Pharmaceutical Industries Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce Full Year Results on May 19, 2021

By Business Wire Business Wire 05-12-2021

Taro to Release First Quarter Results on July 27, 2022

By Business Wire Business Wire 07-26-2022

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro to Announce Full Year Results on May 26, 2022

By Business Wire Business Wire 05-21-2022

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Announce First Quarter Results on July 29, 2020

By Business Wire Business Wire 07-22-2020